Research Analysts Offer Predictions for JANX FY2025 Earnings

Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) - Cantor Fitzgerald boosted their FY2025 earnings estimates for shares of Janux Therapeutics in a report issued on Monday, May 12th. Cantor Fitzgerald analyst J. Schimmer now expects that the company will post earnings per share of ($3.28) for the year, up from their previous estimate of ($3.32). The consensus estimate for Janux Therapeutics' current full-year earnings is ($1.38) per share.

A number of other analysts have also recently weighed in on the stock. Wedbush restated an "outperform" rating and set a $76.00 target price (up from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. HC Wainwright reissued a "buy" rating and set a $70.00 price objective on shares of Janux Therapeutics in a research note on Monday, March 3rd. Finally, Scotiabank decreased their target price on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a report on Friday, February 28th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $95.25.

Janux Therapeutics Stock Performance

Shares of NASDAQ JANX opened at $25.33 on Wednesday. Janux Therapeutics has a 1 year low of $22.52 and a 1 year high of $71.71. The firm has a market cap of $1.50 billion, a P/E ratio of -21.65 and a beta of 3.24. The stock has a fifty day moving average price of $29.06 and a two-hundred day moving average price of $41.29.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.05. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%.

Institutional Trading of Janux Therapeutics

Several large investors have recently modified their holdings of the company. Lester Murray Antman dba SimplyRich grew its holdings in Janux Therapeutics by 205.3% in the 4th quarter. Lester Murray Antman dba SimplyRich now owns 24,315 shares of the company's stock valued at $1,301,000 after buying an additional 16,351 shares during the last quarter. abrdn plc acquired a new position in shares of Janux Therapeutics in the 4th quarter worth approximately $3,430,000. Barclays PLC lifted its holdings in shares of Janux Therapeutics by 496.5% during the third quarter. Barclays PLC now owns 174,061 shares of the company's stock valued at $7,907,000 after acquiring an additional 144,883 shares during the period. Legal & General Group Plc lifted its holdings in Janux Therapeutics by 45.3% during the 4th quarter. Legal & General Group Plc now owns 34,540 shares of the company's stock valued at $1,849,000 after purchasing an additional 10,776 shares during the last quarter. Finally, Rhumbline Advisers grew its position in Janux Therapeutics by 1.6% during the 4th quarter. Rhumbline Advisers now owns 38,153 shares of the company's stock worth $2,043,000 after acquiring an additional 599 shares during the last quarter. 75.39% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, Director Ra Capital Management, L.P. bought 110,206 shares of the business's stock in a transaction on Friday, March 7th. The shares were bought at an average cost of $31.02 per share, for a total transaction of $3,418,590.12. Following the completion of the acquisition, the director now directly owns 10,141,287 shares in the company, valued at approximately $314,582,722.74. This represents a 1.10% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Andrew Hollman Meyer sold 3,333 shares of the business's stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $32.03, for a total value of $106,755.99. Following the completion of the sale, the insider now owns 82,139 shares of the company's stock, valued at approximately $2,630,912.17. This trade represents a 3.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 10,001 shares of company stock worth $313,964. 8.10% of the stock is currently owned by company insiders.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.